JNJ

A guaranteed bank rate sounds safe until you weigh what it can't do.

J&J's Innovative Medicine sees a 7.7% rise in Q3 sales to $16.76 billion, as blockbuster drugs and new launches offset generic headwinds.

When profits dip, lenders get paid first and the dividend is usually what gets cut. Four household names have raised their payouts year after year, and one of them holds a credit rating almost no other U.S. company can match.

Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that could change its income story.

Retirees chasing big yields often get burned, so these four companies took a different route: raising payouts every year for over six decades. Which one has the most cushion, and which carries a risk that could rattle your portfolio?

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is more attractive to value investors?

Some stocks are worth holding for decades, and they usually have one thing in common: a dividend that went up every year through recessions, rate shocks and bear markets.

Smith+Nephew cuts outlook, confirms failed merger talks with J&J's orthopaedics unit

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AbbVie survived its loss of Humira, and its profits are soaring.  J&J's streamlining efforts are paying off.